00:41 , Dec 21, 2016 |  BC Week In Review  |  Clinical News

Neridronic acid regulatory update

Grünenthal said FDA granted breakthrough therapy designation to neridronic acid to treat complex regional pain syndrome (CRPS). The aminobisphosphonate is in Phase III testing and has Fast Track and Orphan Drug designations in the U.S....
07:00 , Jun 2, 2014 |  BC Week In Review  |  Company News

Abiogen, Lee's Pharmaceutical deal

Abiogen granted Lee's Pharmaceutical exclusive rights to commercialize Atilla neridronic acid in China, including Hong Kong and Macau, and Taiwan for osteogenesis imperfecta and complex regional pain syndrome. Osteogenesis imperfecta is characterized by fragile bones...
07:00 , Apr 21, 2014 |  BC Week In Review  |  Clinical News

Nerixia neridronic acid regulatory update

Abiogen and Clinigen Group Ltd. (Burton-on-Trent, U.K.) announced the start of a named-patient program in the EU to provide access to Nerixia neridronic acid to treat osteogenesis imperfecta. Clinigen's Clinigen Global Access Programs (GAP) will...
08:00 , Feb 10, 2014 |  BC Week In Review  |  Company News

Abiogen, EffRx, Atral, Lacer S.A. sales and marketing update

EffRx granted distribution and commercialization rights for Binosto alendronate to Abiogen in Italy, Lacer in Spain and Atral in Portugal. The alendronate effervescent is approved in the U.S., EU and Australia to treat osteoporosis....
07:00 , May 27, 2013 |  BioCentury  |  Strategy

Royalty pain or gain

Elan Corp. plc shareholders have a lot to consider before a June 17 meeting to decide the fate of the biotech. Investors can walk away after pocketing the $6.4 billion proposed by suitor Royalty Pharma,...
07:00 , May 20, 2013 |  BioCentury  |  Emerging Company Profile

Galileo: A TALL order

Galileo Research S.r.L's allogeneic stem cell therapy mimics natural killer cells to stimulate tumor cell apoptosis, but does not attack healthy cells. The off-the-shelf therapy could have broader activity against cancer than allogeneic vaccines in...
08:00 , Nov 2, 2009 |  BC Week In Review  |  Clinical News

ABIO 05/01 regulatory update

EMEA's Committee for Orphan Medicinal Products (COMP) issued a positive opinion to grant Orphan Drug designation to Abiogen's ABIO 05/01 to treat peritoneal carcinosis caused by ovarian cancer. The cytotoxic T cell therapy is in...
07:00 , Jul 16, 2007 |  BC Week In Review  |  Company News

Abiogen, Cancer Research UK deal

Abiogen disclosed that it has an exclusive, worldwide license to a RFB4 murine MAb targeting CD22 from Cancer Research UK's Cancer Research Technology Ltd. subsidiary. Cancer Research will receive an undisclosed upfront payment...
07:00 , Jul 17, 2006 |  BC Week In Review  |  Clinical News

ABIO 08/01: Phase II started

Abiogen began a single-blind Austrian Phase II trial in 20 patients. Abiogen Pharma S.p.A., Pisa, Italy   Product: ABIO 08/01   Business: Neurology   Molecular target: NA   Description: An isoxazoline that stimulates gamma-aminobutyric acid (GABA) release in...
07:00 , Apr 25, 2005 |  BC Week In Review  |  Clinical News

ABIO 05/01: Phase I/II started

Abiogen started an Italian Phase I/II trial in up to 18 patients with advanced tumors who have not responded to existing therapies. Abiogen Pharma S.p.A., Pisa, Italy   Product: ABIO 05/01   Business: Cancer   Molecular target:...